Physician profile
John Jayachandran
NPI 1730164526
$3,121.62
in general payments reported to CMS, 2019-2025
22 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $197 · 2021: $157 · 2022: $459 · 2023: $391 · 2024: $1,449 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Travel and Lodging: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.52 |
| Travel and Lodging | $356.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $803.61 | 2019-2024 | Aveir, Amplatzer Amulet, Mitraclip |
| Biosense Webster, INC. | $460.81 | 2019-2023 | Carto 3 |
| Pfizer INC. | $358.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $181.36 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $178.04 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.85 | 2023-2024 | Jardiance |
| Heartflow, INC. | $133.54 | 2022 | |
| Biotronik INC. | $123.89 | 2024 | Orsiro Mission |
| E.R. Squibb & Sons, L.L.C. | $120.17 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $90.94 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $86.05 | 2019-2024 | Farxiga |
| Inspire Medical Systems, INC. | $80.59 | 2025 | Inspire |
| Boston Scientific Corporation | $78.15 | 2023-2024 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $67.57 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $50.06 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.77 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.21 | 2019-2024 | Lifevest |
| Scpharmaceuticals INC. | $17.43 | 2024 | |
| Ethicon US, LLC | $16.49 | 2025 | Vistaseal |
| Kiniksa Pharmaceuticals, Ltd. | $13.81 | 2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $12.62 | 2025 | Sotalol Hydrochloride |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jayachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.